Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ming Cui has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Yupei Zhao
General Surgery Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
15 shared publications - Quan Liao
Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
11 shared publications - Ya Hu
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 shared publications Jialu Bai
Institute of Clinical Medicine, Peking Union Medical College Hospital, Beiing 100730, China
6 shared publicationsRuiling Xiao
Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
6 shared publicationsDecheng Jiang
Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
5 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by Wolters Kluwer Health in Journal of Pancreatology
Identification of ST3GAL1 as a prognostic sialyltransferase in pancreatic cancer with involvement in CA19-9 synthesis by integrative multiomics analysis
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with distinct tumor biology that drives rapid progression and poor therapeutic response. A prominent feature of PDAC is abnormal glycosylation, especially hypersialylation, which involves excessive sialic acid expression and contributes to tumor growth and immune evasion. Sialyltransferases (STs) mediate hypersialylation; however, the specific enzymes involved in PDAC progression remain unclear. This study aims to identify and characterize key sialyltransferases in PDAC. Methods: We integrated RNA sequencing data and clinical information from PDAC patients obtained from The Cancer Genome Atlas and Genotype-Tissue Expression databases databases. A six-gene prognostic model based on STs expression was developed using Least Absolute Shrinkage and Selection Operator regression and validated across independent PDAC cohorts. Bioinformatic analyses evaluated associations between ST expression and survival outcomes, immune infiltration, immune checkpoint expression, tumor mutational burden, and drug sensitivity. Single-cell RNA sequencing and multiplex immunofluorescence (mIHC) were employed to investigate interactions between ST-expressing tumor cells and immune cells. Functional validation was performed thourgh in vitro knockdown experiments to assess the effects of key ST on carbohydrate antigen (CA)19-9 synthesis in PDAC cells. Results: The STs-based prognostic model showed strong predictive power (area under the curve=0.797), with β-galactoside α-2,3-sialyltransferase 1 (ST3GAL1) contributing most significantly. ST3GAL1 was markedly overexpressed in PDAC compared to normal tissue and was associated with worse overall survival (hazard ratio: 1.45, P ST3GAL1 expression was linked to an immunosuppressive tumor microenvironment characterized by reduced CD8 + T cells, elevated neutrophil infiltration, and increased M2 macrophages. Single-cell analysis and mIHC confirmed a positive correlation between ST3GAL1 + tumor cells and neutrophil infiltration. Notably, ST3GAL1-driven α2,3-sialylation was critical for CA19-9 biosynthesis. Knockdown of ST3GAL1 in PDAC cell lines significantly decreased CA19-9 expression, highlighting its critical role in generating this key tumor biomarker Additionly, ST3GAL1 knockdown predominantly reduced CA19-9 expression and suppressed proliferation and migration in vivo and in vitro . Conclusion: Our integrative analysis highlights ST3GAL1 as a potential key prognostic ST in PDAC, associated with both an immunosuppressive tumor microenvironment and CA19-9 production.
- 16 July 2026
- Published by Wolters Kluwer Health in Journal of Pancreatology
Open AccessIdentification of ST3GAL1 as a prognostic sialyltransferase in pancreatic cancer with involvement in CA19-9 synthesis by integrative multiomics analysis
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with distinct tumor biology that drives rapid progression and poor therapeutic response. A prominent feature of PDAC is abnormal glycosylation, especially hypersialylation, which involves excessive sialic acid expression and contributes to tumor growth and immune evasion. Sialyltransferases (STs) mediate hypersialylation; however, the specific enzymes involved in PDAC progression remain unclear. This study aims to identify and characterize key sialyltransferases in PDAC. Methods: We integrated RNA sequencing data and clinical information from PDAC patients obtained from The Cancer Genome Atlas and Genotype-Tissue Expression databases databases. A six-gene prognostic model based on STs expression was developed using Least Absolute Shrinkage and Selection Operator regression and validated across independent PDAC cohorts. Bioinformatic analyses evaluated associations between ST expression and survival outcomes, immune infiltration, immune checkpoint expression, tumor mutational burden, and drug sensitivity. Single-cell RNA sequencing and multiplex immunofluorescence (mIHC) were employed to investigate interactions between ST-expressing tumor cells and immune cells. Functional validation was performed thourgh in vitro knockdown experiments to assess the effects of key ST on carbohydrate antigen (CA)19-9 synthesis in PDAC cells. Results: The STs-based prognostic model showed strong predictive power (area under the curve=0.797), with β-galactoside α-2,3-sialyltransferase 1 (ST3GAL1) contributing most significantly. ST3GAL1 was markedly overexpressed in PDAC compared to normal tissue and was associated with worse overall survival (hazard ratio: 1.45, P ST3GAL1 expression was linked to an immunosuppressive tumor microenvironment characterized by reduced CD8 + T cells, elevated neutrophil infiltration, and increased M2 macrophages. Single-cell analysis and mIHC confirmed a positive correlation between ST3GAL1 + tumor cells and neutrophil infiltration. Notably, ST3GAL1-driven α2,3-sialylation was critical for CA19-9 biosynthesis. Knockdown of ST3GAL1 in PDAC cell lines significantly decreased CA19-9 expression, highlighting its critical role in generating this key tumor biomarker Additionly, ST3GAL1 knockdown predominantly reduced CA19-9 expression and suppressed proliferation and migration in vivo and in vitro . Conclusion: Our integrative analysis highlights ST3GAL1 as a potential key prognostic ST in PDAC, associated with both an immunosuppressive tumor microenvironment and CA19-9 production.
- 17 April 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 230
Robotic Duodenum-preserving Total Pancreatic Head Resection for Intraductal Papillary Mucinous Neoplasms
Robotic duodenum-preserving pancreatic head resection (R-DPPHR) is a technically feasible procedure for benign or borderline tumors of the pancreatic head. Among these, pancreatic cystic neoplasms (PCNs), particularly intraductal papillary mucinous neoplasms (IPMNs), are ideal candidates for this minimally invasive, organ-preserving approach. While numerous studies have demonstrated the short- and long-term advantages of DPPHR over conventional pancreaticoduodenectomy (PD), detailed video descriptions of the robotic-assisted procedure are scarce. This case report presents a step-by-step technical video of R-DPPHRt for a main duct-IPMN (MD-IPMN) in the pancreatic head. A 65-year-old male patient with upper abdominal discomfort was diagnosed with MD-IPMN, presenting as a 4.3 cm cystic-solid mass in the pancreatic head. R-DPPHRt was performed using the da Vinci Xi system, with an operation time of 350 minutes and an estimated blood loss of 150 mL. The patient had an uneventful postoperative course and was discharged on postoperative day 9. Pathology confirmed MD-IPMN with low-grade dysplasia. R-DPPHRt is an effective, function-preserving treatment for selected patients with pancreatic cystic neoplasms, particularly when performed by experienced surgeons in high-volume centers. While this single-case report limits generalizability, the article offers unique value by providing a clear procedural template.
- 17 April 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 230
Robotic Duodenum-preserving Total Pancreatic Head Resection for Intraductal Papillary Mucinous Neoplasms
Robotic duodenum-preserving pancreatic head resection (R-DPPHR) is a technically feasible procedure for benign or borderline tumors of the pancreatic head. Among these, pancreatic cystic neoplasms (PCNs), particularly intraductal papillary mucinous neoplasms (IPMNs), are ideal candidates for this minimally invasive, organ-preserving approach. While numerous studies have demonstrated the short- and long-term advantages of DPPHR over conventional pancreaticoduodenectomy (PD), detailed video descriptions of the robotic-assisted procedure are scarce. This case report presents a step-by-step technical video of R-DPPHRt for a main duct-IPMN (MD-IPMN) in the pancreatic head. A 65-year-old male patient with upper abdominal discomfort was diagnosed with MD-IPMN, presenting as a 4.3 cm cystic-solid mass in the pancreatic head. R-DPPHRt was performed using the da Vinci Xi system, with an operation time of 350 minutes and an estimated blood loss of 150 mL. The patient had an uneventful postoperative course and was discharged on postoperative day 9. Pathology confirmed MD-IPMN with low-grade dysplasia. R-DPPHRt is an effective, function-preserving treatment for selected patients with pancreatic cystic neoplasms, particularly when performed by experienced surgeons in high-volume centers. While this single-case report limits generalizability, the article offers unique value by providing a clear procedural template.
- Open Access
- 17 March 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (3) , 102660
Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer
- 17 March 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (3) , 102660
Open AccessCancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer
- Top Cited PapersOpen Access
- 26 January 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 28
Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications
Cancer cells orchestrate a highly dynamic and interconnected network spanning metabolic, epigenetic, and immune mechanisms to drive adaptive plasticity and continuous development. This review synthesizes emerging insights into the coevolutionary strategies employed by malignant and stromal cells—particularly tumor cells and immune populations—across the continuum of tumorigenesis, metastasis, and treatment resistance. During tumor initiation, cancer cells rewire metabolism and generate oncometabolites that reshape the chromatin architecture to support immune evasion. Concurrently, metabolic competition in the tumor microenvironment (TME) induces epigenetic exhaustion of cytotoxic T cells, whereas tumor-associated myeloid cells adopt immunosuppressive and angiogenic phenotypes via metabolite-dependent histone modifications to promote carcinogenesis. At metastatic frontiers, under the local metabolic pressure of target organs, tumor cells undergo epigenetic reprogramming to evade immune attacks and support colonization. Premetastatic niches are preconditioned through exosome-mediated transfer of metabolic enzymes and noncoding RNAs that reprogram resident cells before tumor cells arrive. In cancer immunotherapy, tumors often exploit metabolic adaptative strategies to inhibit cell death signaling pathways or the compensatory activation of self-protective mechanisms to circumvent immune-mediated cytotoxicity and develop resistance to immunotherapy. By mapping these dynamic interactions, we propose a novel conceptual framework of the “metabolic-epigenetic-immune axis” that transcends traditional compartmentalized approaches and helps to identify nodal convergence points for therapeutic co-targeting. This review also prioritizes multitarget inhibitors arising from the convergence of metabolic reprogramming, epigenetic plasticity, and immune evasion networks. An integrated approach to these pathways advances next-generation precision oncology strategies aimed at circumventing the evolutionary resilience of cancer.
- 26 January 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 28
Top Cited PapersOpen AccessTargeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications
Cancer cells orchestrate a highly dynamic and interconnected network spanning metabolic, epigenetic, and immune mechanisms to drive adaptive plasticity and continuous development. This review synthesizes emerging insights into the coevolutionary strategies employed by malignant and stromal cells—particularly tumor cells and immune populations—across the continuum of tumorigenesis, metastasis, and treatment resistance. During tumor initiation, cancer cells rewire metabolism and generate oncometabolites that reshape the chromatin architecture to support immune evasion. Concurrently, metabolic competition in the tumor microenvironment (TME) induces epigenetic exhaustion of cytotoxic T cells, whereas tumor-associated myeloid cells adopt immunosuppressive and angiogenic phenotypes via metabolite-dependent histone modifications to promote carcinogenesis. At metastatic frontiers, under the local metabolic pressure of target organs, tumor cells undergo epigenetic reprogramming to evade immune attacks and support colonization. Premetastatic niches are preconditioned through exosome-mediated transfer of metabolic enzymes and noncoding RNAs that reprogram resident cells before tumor cells arrive. In cancer immunotherapy, tumors often exploit metabolic adaptative strategies to inhibit cell death signaling pathways or the compensatory activation of self-protective mechanisms to circumvent immune-mediated cytotoxicity and develop resistance to immunotherapy. By mapping these dynamic interactions, we propose a novel conceptual framework of the “metabolic-epigenetic-immune axis” that transcends traditional compartmentalized approaches and helps to identify nodal convergence points for therapeutic co-targeting. This review also prioritizes multitarget inhibitors arising from the convergence of metabolic reprogramming, epigenetic plasticity, and immune evasion networks. An integrated approach to these pathways advances next-generation precision oncology strategies aimed at circumventing the evolutionary resilience of cancer.
Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer
Background: Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic cancer with highly variable malignant potential. Current understanding of their biology remains incomplete, limiting accurate risk stratification and targeted interventions. Objective: This study aimed to characterise the molecular and immune features of IPMN across different dysplasia grades and histological subtypes, with a focus on IPMN-associated invasive carcinoma (IPMN-IC). Design: Spatial whole-transcriptome profiling using Digital Spatial Profiling was conducted on 12 patients, capturing the full histological and dysplastic spectrum of IPMN and conventional pancreatic ductal adenocarcinoma. A total of 117 epithelial, immune and stromal areas of interest were analysed. An expanded cohort of 43 patients with IPMN was used to validate selected key markers. Results: Transcriptomic analysis unveiled stage-specific molecular alterations and identified two distinct subsets of high-grade (HG) IPMN lesions: one resembling indolent lesions (HG) and the other IC (HG+). Key markers associated with divergent biological behaviours were identified, including MUC5AC and TFF1 in indolent lesions, and Claudin-1 in lesions with invasive potential. Immune profiling revealed a trajectory from activation to suppression during IPMN progression. Several characteristic immune checkpoint molecules, including CEACAM1 and CD44, were identified in IPMN-IC. Conclusion: This study provides a spatially resolved molecular map of IPMN progression, delineating key transcriptomic and immune signatures. These findings advance the understanding of IPMN biology and highlight potential biomarkers for risk stratification and therapeutic strategies.
Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer
Background: Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic cancer with highly variable malignant potential. Current understanding of their biology remains incomplete, limiting accurate risk stratification and targeted interventions. Objective: This study aimed to characterise the molecular and immune features of IPMN across different dysplasia grades and histological subtypes, with a focus on IPMN-associated invasive carcinoma (IPMN-IC). Design: Spatial whole-transcriptome profiling using Digital Spatial Profiling was conducted on 12 patients, capturing the full histological and dysplastic spectrum of IPMN and conventional pancreatic ductal adenocarcinoma. A total of 117 epithelial, immune and stromal areas of interest were analysed. An expanded cohort of 43 patients with IPMN was used to validate selected key markers. Results: Transcriptomic analysis unveiled stage-specific molecular alterations and identified two distinct subsets of high-grade (HG) IPMN lesions: one resembling indolent lesions (HG) and the other IC (HG+). Key markers associated with divergent biological behaviours were identified, including MUC5AC and TFF1 in indolent lesions, and Claudin-1 in lesions with invasive potential. Immune profiling revealed a trajectory from activation to suppression during IPMN progression. Several characteristic immune checkpoint molecules, including CEACAM1 and CD44, were identified in IPMN-IC. Conclusion: This study provides a spatially resolved molecular map of IPMN progression, delineating key transcriptomic and immune signatures. These findings advance the understanding of IPMN biology and highlight potential biomarkers for risk stratification and therapeutic strategies.
- Open Access
- 27 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (10) , 7053-7071
Genomic alterations in pancreatic cystic neoplasms: from molecular characterization to precision clinical management
Pancreatic cystic neoplasms (PCNs) are a heterogeneous group of pancreatic lesions with the potential for malignant transformation. Next-generation sequencing has revealed subtype-specific driver mutations and pathways that govern the initiation and progression of PCN. Evidence suggests that subtype-specific genetic trajectories and temporal sequences of genetic and molecular events are pivotal in determining disease progression and malignant transformation. Novel methodologies in genetic testing, particularly through minimally invasive cyst fluid analysis and advanced tissue-based sequencing, have profoundly enhanced diagnostic accuracy and the molecular classification of PCNs. Furthermore, these genetic insights guide risk stratification, clinical decision-making, and personalized therapeutic interventions. This review systematically summarizes current genomic insights into the molecular landscape of PCNs, critically evaluates the comparative diagnostic performance of cyst fluid versus tissue-based genetic testing, and integrates these findings into a practical framework for clinical management.
- 27 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (10) , 7053-7071
Open AccessGenomic alterations in pancreatic cystic neoplasms: from molecular characterization to precision clinical management
Pancreatic cystic neoplasms (PCNs) are a heterogeneous group of pancreatic lesions with the potential for malignant transformation. Next-generation sequencing has revealed subtype-specific driver mutations and pathways that govern the initiation and progression of PCN. Evidence suggests that subtype-specific genetic trajectories and temporal sequences of genetic and molecular events are pivotal in determining disease progression and malignant transformation. Novel methodologies in genetic testing, particularly through minimally invasive cyst fluid analysis and advanced tissue-based sequencing, have profoundly enhanced diagnostic accuracy and the molecular classification of PCNs. Furthermore, these genetic insights guide risk stratification, clinical decision-making, and personalized therapeutic interventions. This review systematically summarizes current genomic insights into the molecular landscape of PCNs, critically evaluates the comparative diagnostic performance of cyst fluid versus tissue-based genetic testing, and integrates these findings into a practical framework for clinical management.
- Open Access
- 2 June 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-24
FOLR2+ macrophages in cancer: allies or enemies
The advent of the omics era has facilitated the identification of precise biomarkers for cancer progression, revealing a broader diversity of macrophage phenotypes beyond the traditional M1/M2 classification. Folate receptor 2 (FOLR2)-positive macrophages, co-expressing markers such as mannose receptor C-Type 1 (MRC1/CD206) and lymphatic vessel endothelial hyaluronan receptor 1(LYVE1), are an embryonically derived subset typically found around blood vessels in both tumor stroma and normal tissues. Despite FOLR2’s longstanding association with anti-inflammatory, immunosuppressive macrophages in tumors, its precise role in cancer progression remains unclear. Recent studies suggest that FOLR2+ macrophages can either promote or inhibit cancer progression, depending on their multifaceted roles in the tumor microenvironment. This review provides a comprehensive overview of the biological features, functional roles, molecular mechanisms, and therapeutic potential of FOLR2+ macrophages in cancer.
- 2 June 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-24
Open AccessFOLR2+ macrophages in cancer: allies or enemies
The advent of the omics era has facilitated the identification of precise biomarkers for cancer progression, revealing a broader diversity of macrophage phenotypes beyond the traditional M1/M2 classification. Folate receptor 2 (FOLR2)-positive macrophages, co-expressing markers such as mannose receptor C-Type 1 (MRC1/CD206) and lymphatic vessel endothelial hyaluronan receptor 1(LYVE1), are an embryonically derived subset typically found around blood vessels in both tumor stroma and normal tissues. Despite FOLR2’s longstanding association with anti-inflammatory, immunosuppressive macrophages in tumors, its precise role in cancer progression remains unclear. Recent studies suggest that FOLR2+ macrophages can either promote or inhibit cancer progression, depending on their multifaceted roles in the tumor microenvironment. This review provides a comprehensive overview of the biological features, functional roles, molecular mechanisms, and therapeutic potential of FOLR2+ macrophages in cancer.
- 6 May 2025
- Published by Elsevier in Cancer Letters
- Vol. 626, 217773
Sialic Acids: Sweet modulators fueling cancer cells and domesticating the tumor microenvironment
- 6 May 2025
- Published by Elsevier in Cancer Letters
- Vol. 626, 217773
Sialic Acids: Sweet modulators fueling cancer cells and domesticating the tumor microenvironment
- Open Access
- 18 July 2024
- Published by S. Karger AG in Digestive Surgery
- Vol. 41 (3) , 111-121
Lymphocyte-to-Monocyte Ratio Predicts Survival for Intraductal Papillary Mucinous Neoplasm with Associated Invasive Carcinoma of the Pancreas: Results from a High-Volume Center
Introduction: Intraductal papillary mucinous neoplasm (IPMN) is an important precursor lesion of pancreatic cancer. Systemic inflammatory parameters are widely used in the prognosis prediction of cancer; however, their prognostic implications in IPMN with associated invasive carcinoma (IPMN-INV) are unclear. This study aims to explore the prognostic value of systemic inflammatory parameters in patients with IPMN-INV. Methods: From 2015 to 2021, patients with pathologically confirmed IPMN who underwent surgical resection at Peking Union Medical College Hospital were enrolled. The clinical, radiological, and pathological data of the enrolled patients were collected and analyzed. Preoperative systemic inflammatory parameters were calculated as previously reported. Results: Eighty-six patients with IPMN-INV met the inclusion criteria. The lymphocyte-to-monocyte ratio (LMR) was the only systemic inflammatory parameter independently associated with the cancer-specific survival (CSS). An LMR higher than 3.5 was significantly associated with a favorable CSS in univariate (hazard ratio [HR] 0.305, p = 0.003) and multivariate analyses (HR 0.221, p = 0.001). Other independently prognostic factors included the presence of clinical symptoms, cyst size, N stage, and tumor differentiation. Additionally, a model including LMR was established for the prognosis prediction of IPMN-INV and had a C-index of 0.809. Conclusions: Preoperative LMR could serve as a feasible prognostic biomarker for IPMN-INV. A decreased LMR (cutoff value of 3.5) was an independent predictor of poor survival for IPMN-INV.
- 18 July 2024
- Published by S. Karger AG in Digestive Surgery
- Vol. 41 (3) , 111-121
Open AccessLymphocyte-to-Monocyte Ratio Predicts Survival for Intraductal Papillary Mucinous Neoplasm with Associated Invasive Carcinoma of the Pancreas: Results from a High-Volume Center
Introduction: Intraductal papillary mucinous neoplasm (IPMN) is an important precursor lesion of pancreatic cancer. Systemic inflammatory parameters are widely used in the prognosis prediction of cancer; however, their prognostic implications in IPMN with associated invasive carcinoma (IPMN-INV) are unclear. This study aims to explore the prognostic value of systemic inflammatory parameters in patients with IPMN-INV. Methods: From 2015 to 2021, patients with pathologically confirmed IPMN who underwent surgical resection at Peking Union Medical College Hospital were enrolled. The clinical, radiological, and pathological data of the enrolled patients were collected and analyzed. Preoperative systemic inflammatory parameters were calculated as previously reported. Results: Eighty-six patients with IPMN-INV met the inclusion criteria. The lymphocyte-to-monocyte ratio (LMR) was the only systemic inflammatory parameter independently associated with the cancer-specific survival (CSS). An LMR higher than 3.5 was significantly associated with a favorable CSS in univariate (hazard ratio [HR] 0.305, p = 0.003) and multivariate analyses (HR 0.221, p = 0.001). Other independently prognostic factors included the presence of clinical symptoms, cyst size, N stage, and tumor differentiation. Additionally, a model including LMR was established for the prognosis prediction of IPMN-INV and had a C-index of 0.809. Conclusions: Preoperative LMR could serve as a feasible prognostic biomarker for IPMN-INV. A decreased LMR (cutoff value of 3.5) was an independent predictor of poor survival for IPMN-INV.
- 6 July 2024
- Published by Springer Nature
- Vol. 1445, 129-135
Cancer-Derived Immunoglobulin G and Pancreatic Cancer
Immunoglobulin (Ig) is traditionally believed to be produced solely by B cells. Nonetheless, mounting evidence has demonstrated that various types of Igs are extensively expressed in many cell types. Among them, IgG is found to be highly expressed in cancer cells and is thus labeled as cancer-derived IgG. Cancer-derived IgG shares identical fundamental structures with B cell-derived IgG, but displays several unique characteristics, including restricted variable region sequences and unique glycosylation modifications for those expressed by epithelial cancers. Cancer-derived IgG plays multiple crucial roles in carcinogenesis, including facilitating cancer invasion and metastasis, enhancing cancer stemness, contributing to chemoresistance, and remodeling the tumour microenvironment. Recent studies have discovered that cancer-derived sialylated IgG (SIA-IgG) is extensively expressed in pancreatic cancer cells and is predominantly located in the cytoplasm and on the cell membrane. Cancer-derived IgG expressed by pancreatic cancer presents a restrictive variable region sequence and contains a unique sialylation site of the Fab region. Functionally, cancer-derived IgG participates in pancreatic cancer progression via different mechanisms, such as promoting proliferation, facilitating migration and invasion, resisting apoptosis, inducing inflammation, and modulating the tumour microenvironment. SIA-IgG has shown potential as a clinical biomarker. The expression of SIA-IgG is associated with poor tumour differentiation, metastasis, and chemoresistance in pancreatic cancer. High expression of SIA-IgG can serve as an independent prognostic factor for pancreatic cancer. Additionally, SIA-IgG expression elevated with malignant progression for the precursor lesions of pancreatic cancer. These findings present a prospect of applying cancer-derived IgG as a novel diagnostic and therapeutic target in the management of pancreatic cancer, and aiding in overcoming the challenge in the treatment of this stubborn malignancy.
- 6 July 2024
- Published by Springer Nature
- Vol. 1445, 129-135
Cancer-Derived Immunoglobulin G and Pancreatic Cancer
Immunoglobulin (Ig) is traditionally believed to be produced solely by B cells. Nonetheless, mounting evidence has demonstrated that various types of Igs are extensively expressed in many cell types. Among them, IgG is found to be highly expressed in cancer cells and is thus labeled as cancer-derived IgG. Cancer-derived IgG shares identical fundamental structures with B cell-derived IgG, but displays several unique characteristics, including restricted variable region sequences and unique glycosylation modifications for those expressed by epithelial cancers. Cancer-derived IgG plays multiple crucial roles in carcinogenesis, including facilitating cancer invasion and metastasis, enhancing cancer stemness, contributing to chemoresistance, and remodeling the tumour microenvironment. Recent studies have discovered that cancer-derived sialylated IgG (SIA-IgG) is extensively expressed in pancreatic cancer cells and is predominantly located in the cytoplasm and on the cell membrane. Cancer-derived IgG expressed by pancreatic cancer presents a restrictive variable region sequence and contains a unique sialylation site of the Fab region. Functionally, cancer-derived IgG participates in pancreatic cancer progression via different mechanisms, such as promoting proliferation, facilitating migration and invasion, resisting apoptosis, inducing inflammation, and modulating the tumour microenvironment. SIA-IgG has shown potential as a clinical biomarker. The expression of SIA-IgG is associated with poor tumour differentiation, metastasis, and chemoresistance in pancreatic cancer. High expression of SIA-IgG can serve as an independent prognostic factor for pancreatic cancer. Additionally, SIA-IgG expression elevated with malignant progression for the precursor lesions of pancreatic cancer. These findings present a prospect of applying cancer-derived IgG as a novel diagnostic and therapeutic target in the management of pancreatic cancer, and aiding in overcoming the challenge in the treatment of this stubborn malignancy.